BRIDGEWATER, N.J., June 14 /PRNewswire/ -- Aegerion Pharmaceuticals, Inc., a specialty pharmaceutical company focused on the treatment of cardiovascular and metabolic diseases, today announced the company has postponed its initial public offering (IPO).
"The company has decided not to move forward with the proposed IPO at this time," said Jerry Wisler, President and Chief Executive Officer. "The postponement of Aegerion's IPO has no impact on ongoing clinical programs, which continue to progress as scheduled. Aegerion is well capitalized and remains on track to achieve all projected clinical milestones".
About Aegerion Pharmaceuticals, Inc.
Aegerion Pharmaceuticals, Inc. is a privately held specialty pharmaceutical company with a highly experienced senior management team. The company is focused on the development and commercialization of pharmaceuticals to treat cardiovascular and metabolic disease. Its most advanced products are MTP inhibitors which have demonstrated significant clinical effects in Phase II trials in patients with various forms of hyperlipidemia and whose cholesterol levels remain uncontrolled on currently available dyslipidemia therapies. MTP inhibitors represent a potentially new therapeutic approach for hyperlipidemia and a significant commercial opportunity for Aegerion.
Source: Aegerion Pharmaceuticals, Inc.